RSV vaccine Research is Expecting to Accrue Strong Growth in Forecast to 2035 The majority (46%) of the developers were established during the period post-2010. Moreover, there has been an increase in the number of developers entering the RSV vaccine domain over the past decades, reflecting a stable and enticing industry for the new entrants. Examples of developers established post-2020 include (in reverse chronological order, established post-2019) RNApeak (2021), RVAC Medicines (2021), Starna Therapeutics (2021), Vaxmed (2020), Vernagen (2021) and RNAImmune (2020). To view more details on this report, click on the link https://www.rootsanalysis.com/reports/rsv-vaccine-market.html